Primary and metastatic peritoneal surface malignancies

• Published in: Nature reviews. Disease primers Vol. 7; no. 1; p. 91
• Main Authors: Cortés-Guiral, Delia, Hübner, Martin, Alyami, Mohammad, Bhatt, Aditi, Ceelen, Wim, Glehen, Olivier, Lordick, Florian, Ramsay, Robert, Sgarbura, Olivia, Van Der Speeten, Kurt, Turaga, Kiran K., Chand, Manish
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 16-12-2021; Nature Publishing Group
• Subjects: 692/4028; 692/4028/67/322; Cancer Research; Chemotherapy; Combined Modality Therapy; Cytoreduction Surgical Procedures; Epidemiology; Gastric cancer; Humans; Internal Medicine; Medical Microbiology; Medicine; Medicine & Public Health; Metastasis; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - therapy; Primer; Quality of Life; Quality of Life Research; Tumors
• ISSN: 2056-676X; 2056-676X
• DOI: 10.1038/s41572-021-00326-6

Peritoneal surface malignancies comprise a heterogeneous group of primary tumours, including peritoneal mesothelioma, and peritoneal metastases of other tumours, including ovarian, gastric, colorectal, appendicular or pancreatic cancers. The pathophysiology of peritoneal malignancy is complex and not fully understood. The two main hypotheses are the transformation of mesothelial cells (peritoneal primary tumour) and shedding of cells from a primary tumour with implantation of cells in the peritoneal cavity (peritoneal metastasis). Diagnosis is challenging and often requires modern imaging and interventional techniques, including surgical exploration. In the past decade, new treatments and multimodal strategies helped to improve patient survival and quality of life and the premise that peritoneal malignancies are fatal diseases has been dismissed as management strategies, including complete cytoreductive surgery embedded in perioperative systemic chemotherapy, can provide cure in selected patients. Furthermore, intraperitoneal chemotherapy has become an important part of combination treatments. Improving locoregional treatment delivery to enhance penetration to tumour nodules and reduce systemic uptake is one of the most active research areas. The current main challenges involve not only offering the best treatment option and developing intraperitoneal therapies that are equivalent to current systemic therapies but also defining the optimal treatment sequence according to primary tumour, disease extent and patient preferences. New imaging modalities, less invasive surgery, nanomedicines and targeted therapies are the basis for a new era of intraperitoneal therapy and are beginning to show encouraging outcomes.
Peritoneal surface malignancies have heterogeneous origins, including primary peritoneal tumours and metastases of other cancers, for example, digestive tract, reproductive tract, lung, breast and kidney tumours. This Primer reviews the epidemiology, mechanisms and diagnosis of these diseases, and discusses treatment options, patient quality of life and upcoming innovations.